REPL stock forecast
Our latest prediction for Replimune Group, Inc.'s stock price was made on the Nov. 18, 2019 when the stock price was at 11.93$.
In the short term (2weeks), REPL's stock price should outperform the market by 5.45%. During that period the price should oscillate between -9.17% and +15.68%.
In the medium term (3months), REPL's stock price should outperform the market by 6.24%. During that period the price should oscillate between -19.47% and +36.89%.Get email alerts
Create a solid portfolio with REPL
About Replimune Group, Inc.
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in an direct kill turmors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.68$ per share.
The book value per share is 4.11$
Three months stock forecastNov. 18, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|